학술논문
Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children.
Document Type
Article
Author
Seale, Anna C.; Bianchi-Jassir, Fiorella; Russell, Neal J.; Kohli-Lynch, Maya; Tann, Cally J.; Hall, Jenny; Madrid, Lola; Blencowe, Hannah; Cousens, Simon; Baker, Carol J.; Bartlett, Linda; Cutland, Clare; Gravett, Michael G.; Heath, Paul T.; Ip, Margaret; Le Doare, Kirsty; Madhi, Shabir A.; Rubens, Craig E.; Saha, Samir K.; Schrag, Stephanie J.
Source
Subject
*MENINGITIS
*SEPSIS
*STREPTOCOCCAL disease prevention
*DEVELOPMENTAL disabilities
*AGE factors in disease
*CONFIDENCE intervals
*HEALTH
*HOST-bacteria relationships
*PREMATURE infants
*EVALUATION of medical care
*META-analysis
*PERINATAL death
*POSTNATAL care
*PREGNANCY
*PREGNANCY complications
*PREGNANT women
*RESEARCH funding
*STATISTICS
*STREPTOCOCCAL diseases
*UNCERTAINTY
*VACCINES
*SYSTEMATIC reviews
*BIBLIOGRAPHIC databases
*DATA analysis
*DISEASE incidence
*DISEASE prevalence
*VERTICAL transmission (Communicable diseases)
*CEREBRAL anoxia-ischemia
*ANTIBIOTIC prophylaxis
*INTRAPARTUM care
*CHILDREN
*DISEASE risk factors
*DISABILITIES
DEVELOPING countries
RESEARCH evaluation
DEVELOPED countries
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1058-4838
Abstract
Background. We aimed to provide the first comprehensive estimates of the burden of group B Streptococcus (GBS), including invasive disease in pregnant and postpartum women, fetal infection/stillbirth, and infants. Intrapartum antibiotic prophylaxis is the current mainstay of prevention, reducing early-onset infant disease in high-income contexts. Maternal GBS vaccines are in development. Methods. For 2015 live births, we used a compartmental model to estimate (1) exposure to maternal GBS colonization, (2) cases of infant invasive GBS disease, (3) deaths, and (4) disabilities. We applied incidence or prevalence data to estimate cases of maternal and fetal infection/stillbirth, and infants with invasive GBS disease presenting with neonatal encephalopathy. We applied risk ratios to estimate numbers of preterm births attributable to GBS. Uncertainty was also estimated. Results. Worldwide in 2015, we estimated 205 000 (uncertainty range [UR], 101 000-327 000) infants with early-onset disease and 114 000 (UR, 44 000-326 000) with late-onset disease, of whom a minimum of 7000 (UR, 0-19 000) presented with neonatal encephalopathy. There were 90 000 (UR, 36 000-169 000) deaths in infants <3 months age, and, at least 10 000 (UR, 3 000-27 000) children with disability each year. There were 33 000 (UR, 13 000-52 000) cases of invasive GBS disease in pregnant or postpartum women, and 57 000 (UR, 12 000-104 000) fetal infections/stillbirths. Up to 3.5 million preterm births may be attributable to GBS. Africa accounted for 54% of estimated cases and 65% of all fetal/infant deaths. A maternal vaccine with 80% efficacy and 90% coverage could prevent 107 000 (UR, 20 000-198 000) stillbirths and infant deaths. Conclusions. Our conservative estimates suggest that GBS is a leading contributor to adverse maternal and newborn outcomes, with at least 409 000 (UR, 144 000-573 000) maternal/fetal/infant cases and 147 000 (UR, 47 000-273 000) stillbirths and infant deaths annually. An effective GBS vaccine could reduce disease in the mother, the fetus, and the infant. [ABSTRACT FROM AUTHOR]